Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State

Anneleen Daemen, Bonnie Liu, Kyung Song, Mandy Kwong, Min Gao, Rebecca Hong, Michelle Nannini, David Peterson, Bianca M. Liederer, Cecile de la Cruz, Dewakar Sangaraju, Allan Jaochico, Xiaofeng Zhao, Wendy Sandoval, Thomas Hunsaker, Ron Firestein, Sheerin Latham, Deepak Sampath, Marie Evangelista, Georgia Hatzivassiliou

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines expressing GLS1, predominantly through its splice isoform GAC, demonstrated that only GLS1-dependent basal B lines required it for maintaining de novo glutathione synthesis in addition to mitochondrial bioenergetics. Drug sensitivity profiling of 407 tumor lines with GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors revealed a high degree of co-dependency on both enzymes across indications, suggesting that redox balance is a key function of GLS1 in tumors. To leverage these findings, we derived a pan-cancer metabolic signature predictive of GLS1/GCS co-dependency and validated it in vivo using four lung patient-derived xenograft models, revealing the additional requirement for expression of GAC above a threshold (log2RPKM + 1 ≥ 4.5, where RPKM is reads per kilobase per million mapped reads). Analysis of the pan-TCGA dataset with our signature identified multiple indications, including mesenchymal tumors, as putative responders to GLS1 inhibitors. Daemen et al. address the current unmet need for diagnosing responders to glutaminase (GLS1) cancer therapy. They identify co-dependency of GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors, suggesting that redox balance is a key function of GLS1 in tumors, and validate a predictive pan-cancer metabolic signature for GLS1/GCS co-dependency in vivo.

Original languageEnglish
Pages (from-to)383-399
Number of pages27
JournalCell Metabolism
Volume28
Issue number3
DOIs
Publication statusPublished - 4 Sep 2018
Externally publishedYes

Keywords

  • breast cancer
  • GLS1
  • glutaminase dependence
  • glutathione synthesis
  • lung cancer
  • mesenchymal state
  • pharmacodynamic biomarkers
  • predictive gene expression signature
  • redox stress
  • tumor metabolism

Cite this

Daemen, Anneleen ; Liu, Bonnie ; Song, Kyung ; Kwong, Mandy ; Gao, Min ; Hong, Rebecca ; Nannini, Michelle ; Peterson, David ; Liederer, Bianca M. ; de la Cruz, Cecile ; Sangaraju, Dewakar ; Jaochico, Allan ; Zhao, Xiaofeng ; Sandoval, Wendy ; Hunsaker, Thomas ; Firestein, Ron ; Latham, Sheerin ; Sampath, Deepak ; Evangelista, Marie ; Hatzivassiliou, Georgia. / Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. In: Cell Metabolism. 2018 ; Vol. 28, No. 3. pp. 383-399.
@article{201ad9c51e9c4ae985d3bec6ec720949,
title = "Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State",
abstract = "The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines expressing GLS1, predominantly through its splice isoform GAC, demonstrated that only GLS1-dependent basal B lines required it for maintaining de novo glutathione synthesis in addition to mitochondrial bioenergetics. Drug sensitivity profiling of 407 tumor lines with GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors revealed a high degree of co-dependency on both enzymes across indications, suggesting that redox balance is a key function of GLS1 in tumors. To leverage these findings, we derived a pan-cancer metabolic signature predictive of GLS1/GCS co-dependency and validated it in vivo using four lung patient-derived xenograft models, revealing the additional requirement for expression of GAC above a threshold (log2RPKM + 1 ≥ 4.5, where RPKM is reads per kilobase per million mapped reads). Analysis of the pan-TCGA dataset with our signature identified multiple indications, including mesenchymal tumors, as putative responders to GLS1 inhibitors. Daemen et al. address the current unmet need for diagnosing responders to glutaminase (GLS1) cancer therapy. They identify co-dependency of GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors, suggesting that redox balance is a key function of GLS1 in tumors, and validate a predictive pan-cancer metabolic signature for GLS1/GCS co-dependency in vivo.",
keywords = "breast cancer, GLS1, glutaminase dependence, glutathione synthesis, lung cancer, mesenchymal state, pharmacodynamic biomarkers, predictive gene expression signature, redox stress, tumor metabolism",
author = "Anneleen Daemen and Bonnie Liu and Kyung Song and Mandy Kwong and Min Gao and Rebecca Hong and Michelle Nannini and David Peterson and Liederer, {Bianca M.} and {de la Cruz}, Cecile and Dewakar Sangaraju and Allan Jaochico and Xiaofeng Zhao and Wendy Sandoval and Thomas Hunsaker and Ron Firestein and Sheerin Latham and Deepak Sampath and Marie Evangelista and Georgia Hatzivassiliou",
year = "2018",
month = "9",
day = "4",
doi = "10.1016/j.cmet.2018.06.003",
language = "English",
volume = "28",
pages = "383--399",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Elsevier",
number = "3",

}

Daemen, A, Liu, B, Song, K, Kwong, M, Gao, M, Hong, R, Nannini, M, Peterson, D, Liederer, BM, de la Cruz, C, Sangaraju, D, Jaochico, A, Zhao, X, Sandoval, W, Hunsaker, T, Firestein, R, Latham, S, Sampath, D, Evangelista, M & Hatzivassiliou, G 2018, 'Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State' Cell Metabolism, vol. 28, no. 3, pp. 383-399. https://doi.org/10.1016/j.cmet.2018.06.003

Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. / Daemen, Anneleen; Liu, Bonnie; Song, Kyung; Kwong, Mandy; Gao, Min; Hong, Rebecca; Nannini, Michelle; Peterson, David; Liederer, Bianca M.; de la Cruz, Cecile; Sangaraju, Dewakar; Jaochico, Allan; Zhao, Xiaofeng; Sandoval, Wendy; Hunsaker, Thomas; Firestein, Ron; Latham, Sheerin; Sampath, Deepak; Evangelista, Marie; Hatzivassiliou, Georgia.

In: Cell Metabolism, Vol. 28, No. 3, 04.09.2018, p. 383-399.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State

AU - Daemen, Anneleen

AU - Liu, Bonnie

AU - Song, Kyung

AU - Kwong, Mandy

AU - Gao, Min

AU - Hong, Rebecca

AU - Nannini, Michelle

AU - Peterson, David

AU - Liederer, Bianca M.

AU - de la Cruz, Cecile

AU - Sangaraju, Dewakar

AU - Jaochico, Allan

AU - Zhao, Xiaofeng

AU - Sandoval, Wendy

AU - Hunsaker, Thomas

AU - Firestein, Ron

AU - Latham, Sheerin

AU - Sampath, Deepak

AU - Evangelista, Marie

AU - Hatzivassiliou, Georgia

PY - 2018/9/4

Y1 - 2018/9/4

N2 - The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines expressing GLS1, predominantly through its splice isoform GAC, demonstrated that only GLS1-dependent basal B lines required it for maintaining de novo glutathione synthesis in addition to mitochondrial bioenergetics. Drug sensitivity profiling of 407 tumor lines with GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors revealed a high degree of co-dependency on both enzymes across indications, suggesting that redox balance is a key function of GLS1 in tumors. To leverage these findings, we derived a pan-cancer metabolic signature predictive of GLS1/GCS co-dependency and validated it in vivo using four lung patient-derived xenograft models, revealing the additional requirement for expression of GAC above a threshold (log2RPKM + 1 ≥ 4.5, where RPKM is reads per kilobase per million mapped reads). Analysis of the pan-TCGA dataset with our signature identified multiple indications, including mesenchymal tumors, as putative responders to GLS1 inhibitors. Daemen et al. address the current unmet need for diagnosing responders to glutaminase (GLS1) cancer therapy. They identify co-dependency of GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors, suggesting that redox balance is a key function of GLS1 in tumors, and validate a predictive pan-cancer metabolic signature for GLS1/GCS co-dependency in vivo.

AB - The enzyme glutaminase (GLS1) is currently in clinical trials for oncology, yet there are no clear diagnostic criteria to identify responders. The evaluation of 25 basal breast lines expressing GLS1, predominantly through its splice isoform GAC, demonstrated that only GLS1-dependent basal B lines required it for maintaining de novo glutathione synthesis in addition to mitochondrial bioenergetics. Drug sensitivity profiling of 407 tumor lines with GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors revealed a high degree of co-dependency on both enzymes across indications, suggesting that redox balance is a key function of GLS1 in tumors. To leverage these findings, we derived a pan-cancer metabolic signature predictive of GLS1/GCS co-dependency and validated it in vivo using four lung patient-derived xenograft models, revealing the additional requirement for expression of GAC above a threshold (log2RPKM + 1 ≥ 4.5, where RPKM is reads per kilobase per million mapped reads). Analysis of the pan-TCGA dataset with our signature identified multiple indications, including mesenchymal tumors, as putative responders to GLS1 inhibitors. Daemen et al. address the current unmet need for diagnosing responders to glutaminase (GLS1) cancer therapy. They identify co-dependency of GLS1 and gamma-glutamylcysteine synthetase (GCS) inhibitors, suggesting that redox balance is a key function of GLS1 in tumors, and validate a predictive pan-cancer metabolic signature for GLS1/GCS co-dependency in vivo.

KW - breast cancer

KW - GLS1

KW - glutaminase dependence

KW - glutathione synthesis

KW - lung cancer

KW - mesenchymal state

KW - pharmacodynamic biomarkers

KW - predictive gene expression signature

KW - redox stress

KW - tumor metabolism

UR - http://www.scopus.com/inward/record.url?scp=85048800855&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2018.06.003

DO - 10.1016/j.cmet.2018.06.003

M3 - Article

VL - 28

SP - 383

EP - 399

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 3

ER -